Drug Profile
Tocilizumab biosimilar - Fresenius Kabi
Alternative Names: MSB-11456; TyenneLatest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator Merck KGaA
- Developer Fresenius Kabi
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Autoimmune disorders; COVID 2019 infections; Cytokine release syndrome; Giant cell arteritis; Juvenile rheumatoid arthritis; Rheumatoid arthritis